Cited 0 times in
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2021-09-29T00:30:54Z | - |
dc.date.available | 2021-09-29T00:30:54Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/183884 | - |
dc.description.abstract | Purpose: The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)-induced nausea and vomiting. Materials and methods: Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by sex, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6. Results: A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], -7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, -2.3%; 95% CI, -13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, -7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups. Conclusion: In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiemetics / therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects* | - |
dc.subject.MESH | Aprepitant / therapeutic use | - |
dc.subject.MESH | Benzimidazoles / therapeutic use | - |
dc.subject.MESH | Dexamethasone / therapeutic use | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Nausea / chemically induced | - |
dc.subject.MESH | Nausea / drug therapy* | - |
dc.subject.MESH | Nausea / pathology | - |
dc.subject.MESH | Neoplasms / drug therapy* | - |
dc.subject.MESH | Neoplasms / pathology | - |
dc.subject.MESH | Palonosetron / therapeutic use | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quality of Life* | - |
dc.subject.MESH | Surveys and Questionnaires | - |
dc.subject.MESH | Vomiting / chemically induced | - |
dc.subject.MESH | Vomiting / drug therapy* | - |
dc.subject.MESH | Vomiting / pathology | - |
dc.subject.MESH | Young Adult | - |
dc.title | Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jin Hyoung Kang | - |
dc.contributor.googleauthor | Jung Hye Kwon | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Ho Jung An | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Young Mi Seol | - |
dc.contributor.googleauthor | Hyunwoo Lee | - |
dc.contributor.googleauthor | Hwan-Jung Yun | - |
dc.contributor.googleauthor | Jin Seok Ahn | - |
dc.contributor.googleauthor | Ji Hyun Yang | - |
dc.contributor.googleauthor | Hunho Song | - |
dc.contributor.googleauthor | Dong-Hoe Koo | - |
dc.contributor.googleauthor | Jin Young Kim | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Hwa Jung Kim | - |
dc.identifier.doi | 10.4143/crt.2019.713 | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 32192275 | - |
dc.subject.keyword | Antiemetics | - |
dc.subject.keyword | Aprepitant | - |
dc.subject.keyword | Nausea | - |
dc.subject.keyword | Neoplasms | - |
dc.subject.keyword | Palonosetron | - |
dc.subject.keyword | Ramosetron | - |
dc.subject.keyword | Vomiting | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | 김건민 | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 52 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 907 | - |
dc.citation.endPage | 916 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.52(3) : 907-916, 2020-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.